Compare Bristol-Myers Squibb Co (BMY) vs iShares Broad USD Investment Grade Corporate Bond (USIG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs iShares Broad USD Investment Grade Corporate Bond — how do they compare? Bristol-Myers Squibb Co trades at $57 (market cap $116.30B), while iShares Broad USD Investment Grade Corporate Bond trades at $50.61. The key difference: Bristol-Myers Squibb Co pays a 4.42% dividend while iShares Broad USD Investment Grade Corporate Bond pays none, and Bristol-Myers Squibb Co is trading nearer its 52-week high, iShares Broad USD Investment Grade Corporate Bond nearer its low. Which is the better fit depends on your goals.
| BMY | USIG | |
|---|---|---|
Market Cap | $116.30B | — |
Sector | Health | Fixed Income |
52-Week High | $62.37 | $52.69 |
52-Week Low | $42.60 | $50.50 |
Enterprise Value | $152.24B | — |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
USIG trades at $50.50, down 0.4% with bearish technical signals from moving averages but oversold RSI readings. The ETF shows consistent dividend distributions with three payments scheduled for mid-2026. Short interest surged 63.4% in April 2026, indicating increased bearish sentiment among traders despite the investment-grade corporate bond focus.
The ETF faces headwinds from rising short interest and bearish technical momentum, though oversold conditions suggest potential near-term stabilization. Investment-grade corporate bond exposure provides relative safety, but interest rate sensitivity remains a key risk factor for fixed income ETFs in the current market environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About iShares Broad USD Investment Grade Corporate Bond
USIG is a low-cost ETF providing broad exposure to over 11,000 U.S. investment-grade corporate bonds. It tracks the ICE BofA US Corporate Index, featuring high-quality debt from 2026 leaders like Citigroup, Bank of America, and Oracle.
Read more on USIG →
